» Articles » PMID: 35873037

Nanomaterials-Mediated Therapeutics and Diagnosis Strategies for Myocardial Infarction

Overview
Journal Front Chem
Specialty Chemistry
Date 2022 Jul 25
PMID 35873037
Authors
Affiliations
Soon will be listed here.
Abstract

The alarming mortality and morbidity rate of myocardial infarction (MI) is becoming an important impetus in the development of early diagnosis and appropriate therapeutic approaches, which are critical for saving patients' lives and improving post-infarction prognosis. Despite several advances that have been made in the treatment of MI, current strategies are still far from satisfactory. Nanomaterials devote considerable contribution to tackling the drawbacks of conventional therapy of MI by improving the homeostasis in the cardiac microenvironment via targeting, immune modulation, and repairment. This review emphasizes the strategies of nanomaterials-based MI treatment, including cardiac targeting drug delivery, immune-modulation strategy, antioxidants and antiapoptosis strategy, nanomaterials-mediated stem cell therapy, and cardiac tissue engineering. Furthermore, nanomaterials-based diagnosis strategies for MI was presented in term of nanomaterials-based immunoassay and nano-enhanced cardiac imaging. Taken together, although nanomaterials-based strategies for the therapeutics and diagnosis of MI are both promising and challenging, such a strategy still explores the immense potential in the development of the next generation of MI treatment.

Citing Articles

The clinical prospects and challenges of photothermal nanomaterials in myocardium recovery after myocardial infarction.

Yang J, He J, Yue T, Pei H, Xiong S, Tang Y Front Bioeng Biotechnol. 2024; 12:1491581.

PMID: 39539693 PMC: 11558533. DOI: 10.3389/fbioe.2024.1491581.


Research progress on the natural products in the intervention of myocardial infarction.

Guo Q, Wang J, Ni C, Pan J, Zou J, Shi Y Front Pharmacol. 2024; 15:1445349.

PMID: 39239656 PMC: 11374734. DOI: 10.3389/fphar.2024.1445349.


A Biomimetic Nanocarrier Strategy Targets Ferroptosis and Efferocytosis During Myocardial Infarction.

Song L, Yuan X, Zhao Z, Wang P, Wu W, Wang J Int J Nanomedicine. 2024; 19:8253-8270.

PMID: 39157734 PMC: 11330256. DOI: 10.2147/IJN.S461212.


Nanomedicine And Nanotheranostics: Special Focus on Imaging of Anticancer Drugs Induced Cardiac Toxicity.

Setia A, Challa R, Vallamkonda B, Satti P, Mehata A, Priya V Nanotheranostics. 2024; 8(4):473-496.

PMID: 38961885 PMC: 11217786. DOI: 10.7150/ntno.96846.


Advanced Nanomedicine Approaches for Myocardial Infarction Treatment.

Song L, Jia K, Yang F, Wang J Int J Nanomedicine. 2024; 19:6399-6425.

PMID: 38952676 PMC: 11215519. DOI: 10.2147/IJN.S467219.


References
1.
Zhou Q, Zeng Y, Xiong Q, Zhong S, Li P, Ran H . Construction of CNA35 Collagen-Targeted Phase-Changeable Nanoagents for Low-Intensity Focused Ultrasound-Triggered Ultrasound Molecular Imaging of Myocardial Fibrosis in Rabbits. ACS Appl Mater Interfaces. 2019; 11(26):23006-23017. DOI: 10.1021/acsami.9b05999. View

2.
Nie J, Qiao B, Duan S, Xu C, Chen B, Hao W . Unlockable Nanocomplexes with Self-Accelerating Nucleic Acid Release for Effective Staged Gene Therapy of Cardiovascular Diseases. Adv Mater. 2018; 30(31):e1801570. DOI: 10.1002/adma.201801570. View

3.
Cheraghi M, Negahdari B, Daraee H, Eatemadi A . Heart targeted nanoliposomal/nanoparticles drug delivery: An updated review. Biomed Pharmacother. 2016; 86:316-323. DOI: 10.1016/j.biopha.2016.12.009. View

4.
Li J, Minami I, Shiozaki M, Yu L, Yajima S, Miyagawa S . Human Pluripotent Stem Cell-Derived Cardiac Tissue-like Constructs for Repairing the Infarcted Myocardium. Stem Cell Reports. 2017; 9(5):1546-1559. PMC: 5829319. DOI: 10.1016/j.stemcr.2017.09.007. View

5.
Neumann F, Sousa-Uva M, Ahlsson A, Alfonso F, Banning A, Benedetto U . 2018 ESC/EACTS Guidelines on myocardial revascularization. EuroIntervention. 2019; 14(14):1435-1534. DOI: 10.4244/EIJY19M01_01. View